Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Vlado PerkovicKatherine R TuttleEllen BurgessKenneth W MahaffeyJohannes F E MannGeorge L BakrisFlorian M M BaeresThomas IdornHeidrun Bosch-TrabergNanna Leonora LausvigRichard Pratleynull nullPublished in: The New England journal of medicine (2024)
Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. (Funded by Novo Nordisk; FLOW ClinicalTrials.gov number, NCT03819153.).